Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$0.14 - $0.26 $1,653 - $3,071
11,814 Added 11469.9%
11,917 $2,000
Q1 2024

May 13, 2024

SELL
$0.13 - $0.23 $1,148 - $2,031
-8,833 Reduced 98.85%
103 $0
Q4 2023

Feb 09, 2024

BUY
$0.14 - $0.77 $1,251 - $6,880
8,936 New
8,936 $1,000
Q4 2022

Feb 08, 2023

SELL
$1.01 - $53.8 $2,606 - $138,857
-2,581 Reduced 46.87%
2,926 $3,000
Q3 2022

Nov 10, 2022

BUY
$2.18 - $43.4 $10,544 - $209,925
4,837 Added 721.94%
5,507 $12,000
Q2 2022

Aug 10, 2022

SELL
$2.65 - $4.12 $8,116 - $12,619
-3,063 Reduced 82.05%
670 $2,000
Q1 2022

May 16, 2022

BUY
$2.65 - $4.84 $6,076 - $11,098
2,293 Added 159.24%
3,733 $15,000
Q4 2021

Feb 14, 2022

SELL
$4.32 - $6.27 $5,235 - $7,599
-1,212 Reduced 45.7%
1,440 $7,000
Q3 2021

Nov 15, 2021

BUY
$5.23 - $8.89 $3,446 - $5,858
659 Added 33.07%
2,652 $15,000
Q2 2021

Aug 13, 2021

BUY
$7.12 - $9.15 $14,190 - $18,235
1,993 New
1,993 $15,000
Q1 2021

May 12, 2021

SELL
$6.81 - $9.64 $7,586 - $10,738
-1,114 Closed
0 $0
Q4 2020

Feb 11, 2021

SELL
$6.13 - $9.08 $404 - $599
-66 Reduced 5.59%
1,114 $8,000
Q3 2020

Nov 12, 2020

BUY
$6.35 - $9.8 $7,493 - $11,564
1,180 New
1,180 $10,000
Q2 2020

Jul 31, 2020

SELL
$4.72 - $9.7 $2,798 - $5,752
-593 Closed
0 $0
Q1 2020

May 01, 2020

SELL
$3.71 - $6.05 $7,828 - $12,765
-2,110 Reduced 78.06%
593 $3,000
Q4 2019

Feb 14, 2020

BUY
$3.94 - $6.45 $1,343 - $2,199
341 Added 14.44%
2,703 $12,000
Q3 2019

Nov 14, 2019

SELL
$5.01 - $7.8 $8,000 - $12,456
-1,597 Reduced 40.34%
2,362 $14,000
Q2 2019

Aug 14, 2019

BUY
$6.39 - $8.91 $25,298 - $35,274
3,959 New
3,959 $31,000

Others Institutions Holding SNOA

# of Institutions
1
Shares Held
2.27K
Call Options Held
0
Put Options Held
0

About Sonoma Pharmaceuticals, Inc.


  • Ticker SNOA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 3,100,940
  • Market Cap $8.84M
  • Description
  • Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription ...
More about SNOA
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.